
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>




































This protein carries a human IgG1 Fc tag at the N-terminus.
The protein has a calculated MW of 32.3 kDa. The protein migrates as 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:

Human CXCR4, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Plerixafor | SDZ-SID-791; JM-3100; JKL-169; AMD-3100; PLR-001; LM-3100 | Approved | Genzyme Corp | Mozobil, Mobozil, 释倍灵 | Mainland China | Lymphoma, Non-Hodgkin; Multiple Myeloma | Genzyme Europe Bv | 2008-12-15 | Colorectal Neoplasms; Rejection of organ transplantation; Sarcoma, Ewing; Brain Neoplasms; Neuroblastoma; Leukopenia; Osteosarcoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Agranulocytosis; Lymphopenia; Pulmonary Fibrosis; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Pulmonary Disease, Chronic Obstructive; Granulomatous Disease, Chronic; Lymphoma; Anemia, Sickle Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Adenocarcinoma; Primary Graft Dysfunction; Hematopoietic stem cell transplantation (HSCT); Cystic Fibrosis; Wiskott-Aldrich Syndrome; Bone metastases; Hematologic Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Warts; Agammaglobulinemia; Infections; Hodgkin Disease; Fanconi Anemia; Neoplasms; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Pancreatic Neoplasms; Multiple Myeloma | Details |
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| USL-311 | USL-311 | Ligand Pharmaceuticals Inc | Details | ||
| PF-06747143 | PF-06747143 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
| LEO-35299 | LEO-35299 | Leo Pharma A/S | Details | ||
| Balixafortide | POL-6326 | Phase 1 Clinical | Polyphor Ltd | Breast Neoplasms | Details |
| LY-2510924 | T-134; LY-2510924 | Eli Lilly And Company | Details | ||
| CGT-1881 | CGT1881; CGT-1881 | Phase 1 Clinical | Cgenetech(Suzhou China) Co Ltd | Hematologic Neoplasms; Multiple Myeloma; Lymphoma, Non-Hodgkin | Details |
| PTX-9908 | PTX-9908 | Phase 2 Clinical | Pertinax Therapeutics | Carcinoma, Hepatocellular | Details |
| X-4136 | X-4136 | Clinical | X4 Pharmaceuticals Inc | Lymphoma, B-Cell | Details |
| NRP-2945 | NNZ-4945; NRP-2945 | Phase 2 Clinical | Neuren Pharmaceuticals Ltd | Epilepsy | Details |
| 68Ga-Pentixather | 68Ga-Pentixather | Phase 1 Clinical | Peking Union Medical College Hospital | Multiple Myeloma | Details |
| Ulocuplumab | MDX-1338; BMS-936564 | Phase 2 Clinical | Bristol-Myers Squibb Company | Leukemia; Solid tumours; Multiple Myeloma; Lymphoma, Follicular; Leukemia, B-Cell; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| 212-Lead Pentixather | Phase 1 Clinical | National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center | Small Cell Lung Carcinoma; Lung Neoplasms | Details | |
| 203-Lead Pentixather | Phase 1 Clinical | National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center | Small Cell Lung Carcinoma; Lung Neoplasms | Details | |
| [68Ga]Pentixafor | Phase 2 Clinical | The University Of Iowa | Neuroendocrine Tumors; Central Nervous System Neoplasms | Details | |
| JVS-100 | ACRX-100; GP-51801; GP51801; JVS-100; SRX-100 | Phase 1 Clinical | Cleveland Clinic | Heart Failure; Surgical Wound; Ischemia; Peripheral Arterial Disease | Details |
| AD-214 | AD-214 | Phase 1 Clinical | Addpharma Inc, Adalta Ltd | Lung Diseases, Interstitial; Gastroesophageal Reflux | Details |
| 4-P-021 | 4P021; 4-P-021 | Phase 2 Clinical | 4P-Pharma Ltd, University of Bordeaux, Institut Pasteur De Lille | Coronavirus Disease 2019 (COVID-19) | Details |
| GPC-100 | GPC-100 | Phase 2 Clinical | GPCR Therapeutics USA Inc | Multiple Myeloma | Details |
| MB-1707 | MB-1707 | Phase 1 Clinical | Mainline Biosciences Inc | Solid tumours; Ovarian Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Motixafortide | 4F-Benzoyl-TN14003; TN-14003; TF-14016; BL-8040; BKT-140; GFH-168 | Phase 3 Clinical | Biokine | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Lymphoid; Esophageal Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Hodgkin Disease; Multiple Myeloma; Anemia, Aplastic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Adenocarcinoma; Anemia, Sickle Cell | Details |
| Mavorixafor | AMD-11070; X4P-001-IO; AMD-070; X4P-001; X4P-001-RD; X4P-001-LD; ABSK-081 | Phase 3 Clinical | Genzyme Corp | HIV Infections; Carcinoma, Renal Cell; WHIM syndrome; Neutropenia; Triple Negative Breast Neoplasms; Waldenstrom Macroglobulinemia; Melanoma | Details |
This web search service is supported by Google Inc.




